UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

ABB has introduced significant advancements to the power simulation models for its ABB UNITROL 1000 Automatic Voltage Regulators (AVR).

As explained in Prof. Robert Jarrow’s book cited below, forward rates contain a risk premium above and beyond the market’s expectations for the 3-month forward rate. We document the size of that risk ...

That will complete the second of the MCU's two Sagas to date, both of which contain three Phases. If this sounds like a lot, we don't blame you as there's a lot to keep up from 18 years of Marvel ...